{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:04:20Z","timestamp":1784099060023,"version":"3.55.0"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Oncol. Rev."],"abstract":"<jats:p>Prostate cancer remains a leading cause of cancer-related morbidity and mortality among men, and metastatic castration-resistant prostate cancer continues to present substantial therapeutic challenges despite advances in androgen receptor pathway inhibitors, taxane chemotherapy, PARP inhibitors, and immunotherapy for selected molecular subgroups. Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy has emerged as a clinically important theranostic strategy that combines molecular imaging-based patient selection with targeted delivery of cytotoxic radiation to PSMA-expressing tumor sites. This narrative review summarizes the biological rationale, clinical evidence, safety profile, and evolving treatment-sequencing considerations for PSMA-targeted radioligand therapy in advanced prostate cancer. Particular emphasis is placed on ^177Lu-PSMA-617, which has demonstrated improved radiographic progression-free survival and overall survival in pivotal randomized trials, including VISION, TheraP, and PSMAfore. The review also examines investigational alpha-emitting PSMA-targeted therapies, particularly ^225Ac-PSMA compounds, which offer high-linear-energy-transfer cytotoxicity and may have activity in selected patients after progression on beta-emitting radioligand therapy, although definitive phase III evidence remains lacking. The established bone-targeted alpha-emitter ^223Ra is discussed separately as contextual therapy for selected patients with symptomatic bone-predominant mCRPC without visceral metastases. As clinical use of radioligand therapy expands, optimization of PSMA PET-based patient selection, management of salivary, hematologic, and renal toxicities, sequencing with other systemic therapies, and integration into multidisciplinary care pathways will be essential. Future research should prioritize randomized clinical trials, individualized dosimetry, predictive biomarkers, toxicity mitigation, and patient-centered implementation strategies.<\/jats:p>","DOI":"10.3389\/or.2026.1834484","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:05:23Z","timestamp":1784095523000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["PSMA-targeted radioligand therapy in advanced prostate cancer: a narrative review of ^177Lu-PSMA, emerging ^225Ac-PSMA strategies, and therapeutic sequencing"],"prefix":"10.3389","volume":"20","author":[{"given":"Natalia","family":"Gierulska","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology and Chemotherapy, Student Scientific Society, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Jankowska","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Chemotherapy, Student Scientific Society, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianna","family":"Kwiatkowska","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Chemotherapy, Student Scientific Society, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Kuchno","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Chemotherapy, Student Scientific Society, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"\u0141ysak","sequence":"additional","affiliation":[{"name":"Copernicus Hospital","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Szklener","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Chemotherapy, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Ko\u015bmider","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Chemotherapy, Medical University of Lublin","place":["Lublin, Poland"]},{"name":"Department of Pneumonology, Oncology and Allergology, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Sk\u00f3rzewska","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Chemotherapy, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/molecules27175730","article-title":"Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches","volume":"27","author":"Sekhoacha","year":"2022","journal-title":"Molecules"},{"key":"B2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"14257","DOI":"10.3390\/ijms232214257","article-title":"Complexities of prostate cancer","volume":"23","author":"Wasim","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1158\/1055-9965.EPI-13-0568","article-title":"The heritability of prostate cancer in the nordic twin study of cancer","volume":"23","author":"Hjelmborg","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"901578","DOI":"10.1155\/2013\/901578","article-title":"Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era","volume":"2013","author":"Chen","year":"2013","journal-title":"Biomed Res Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.3390\/cancers17213412","article-title":"Radioligand therapy in cancer management: a global perspective","volume":"17","author":"Ninatti","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"102940","DOI":"10.1016\/j.ctrv.2025.102940","article-title":"Radioligand therapy in metastatic breast cancer: harnessing precision oncology","volume":"136","author":"Giugliano","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.3390\/molecules27175429","article-title":"Radionuclides for targeted therapy: physical properties","volume":"27","author":"Stokke","year":"2022","journal-title":"Molecules"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.3390\/molecules27154959","article-title":"Application of cleavable linkers to improve therapeutic index of radioligand therapies","volume":"27","author":"Lau","year":"2022","journal-title":"Molecules"},{"key":"B11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/14737140.2023.2213892","article-title":"Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review","volume":"23","author":"Patell","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"B12","first-page":"555","article-title":"Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises","volume":"28","author":"Santoni","year":"2014","journal-title":"J Biol Regul Homeost Agents"},{"key":"B13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/s0090-4295(98)00278-7","article-title":"Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases","volume":"52","author":"Sweat","year":"1998","journal-title":"Urology"},{"key":"B14","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1053\/j.semnuclmed.2019.07.003","article-title":"PSMA-based theranostics: a step-by-step practical approach to diagnosis and therapy for mCRPC patients","volume":"50","author":"Ahmadzadehfar","year":"2020","journal-title":"Semin Nucl Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/jmrs.227","article-title":"Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy","volume":"64","author":"Emmett","year":"2017","journal-title":"J Med Radiat Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/jcb.21491","article-title":"Targeted treatment of prostate cancer","volume":"102","author":"Wang","year":"2007","journal-title":"J Cel Biochem"},{"key":"B18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40658-022-00497-5","article-title":"Impact of radiopharmaceutical therapy (177Lu, 225Ac) microdistribution in a cancer-associated fibroblasts model","volume":"9","author":"Tranel","year":"2022","journal-title":"EJNMMI Phys"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00259-020-05057-6","article-title":"Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy","volume":"48","author":"Ruigrok","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-04-2244","article-title":"First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases","volume":"11","author":"Nilsson","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"6250s","DOI":"10.1158\/1078-0432.CCR-06-0841","article-title":"High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?","volume":"12","author":"Bruland","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B25","first-page":"3120","article-title":"Significant antitumor effect from bone-seeking, alpha-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model","volume":"62","author":"Henriksen","year":"2002","journal-title":"Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"17588359231157632","DOI":"10.1177\/17588359231157632","article-title":"Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials","volume":"15","author":"Jang","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/pharmaceutics13010049","article-title":"Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications","volume":"13","author":"Nelson","year":"2020","journal-title":"Pharmaceutics"},{"key":"B30","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3390\/pharmaceutics13060906","article-title":"Overview of the most promising radionuclides for targeted alpha therapy: the \u201chopeful eight\u201d","volume":"13","author":"Eychenne","year":"2021","journal-title":"Pharmaceutics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1053\/j.semnuclmed.2024.03.004","article-title":"Advances in PSMA alpha theragnostics","volume":"54","author":"Vorster","year":"2024","journal-title":"Semin Nucl Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1093\/annonc\/mdz270","article-title":"Advances in targeted alpha therapy for prostate cancer","volume":"30","author":"De Vincentis","year":"2019","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.21037\/atm-23-1842","article-title":"Design of 225Ac-PSMA for targeted alpha therapy in prostate cancer","volume":"12","author":"Kairemo","year":"2024","journal-title":"Ann Transl Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1159\/000531246","article-title":"Efficacy and safety of actinium-225 prostate-specific membrane antigen radioligand therapy in metastatic prostate cancer: a systematic review and metanalysis","volume":"32","author":"Parida","year":"2023","journal-title":"Med Princ Pract"},{"key":"B35","doi-asserted-by":"publisher","first-page":"348","DOI":"10.4103\/jcrt.JCRT_892_18","article-title":"Calculation of radium-223 and actinium-225 \u03b1-emitter radiopharmaceuticals dose rates in treatment of metastatic castration-resistant prostate cancer","volume":"17","author":"Abbasi","year":"2021","journal-title":"J Cancer Res Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"840","DOI":"10.2967\/jnumed.121.262017","article-title":"Effects of 225Ac-labeled prostate-specific membrane antigen radioligand therapy in metastatic castration-resistant prostate cancer: a meta-analysis","volume":"63","author":"Lee","year":"2022","journal-title":"J Nucl Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3390\/ijms25020933","article-title":"Comparison of nuclear medicine therapeutics targeting PSMA among alpha-emitting nuclides","volume":"25","author":"Kaneda-Nakashima","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"11626","DOI":"10.3390\/ijms241411626","article-title":"Targeted alpha-particle therapy: a review of current trials","volume":"24","author":"Jang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.7150\/thno.96403","article-title":"Actinium-225 targeted alpha particle therapy for prostate cancer","volume":"14","author":"Bidkar","year":"2024","journal-title":"Theranostics"},{"key":"B40","doi-asserted-by":"publisher","first-page":"15172","DOI":"10.1073\/pnas.1918744117","article-title":"Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted \u03b1-particle therapy","volume":"117","author":"Bicak","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00259-018-4167-0","article-title":"225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study","volume":"46","author":"Sathekge","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B43","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA","volume":"79","author":"Feuerecker","year":"2021","journal-title":"Eur Urol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1516860","DOI":"10.3389\/fonc.2025.1516860","article-title":"The efficacy and safety of 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer","volume":"15","author":"Ma","year":"2025","journal-title":"Front Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s41181-024-00239-1","article-title":"Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives","volume":"9","author":"Hooijman","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"key":"B46","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1007\/s00259-025-07168-4","article-title":"Evaluating xerostomia as a side effect of [255Ac]Ac-PSMA therapy in prostate cancer: a systematic review and meta-analysis","volume":"52","author":"Al-Ibraheem","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B48","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00259-018-4135-8","article-title":"Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT","volume":"46","author":"Rathke","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B49","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s13139-017-0508-3","article-title":"Injection of botulinum toxin for preventing salivary gland toxicity after PSMA radioligand therapy: an empirical proof of a promising concept","volume":"52","author":"Baum","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"key":"B50","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13550-018-0408-2","article-title":"Impact of external cooling with icepacks on 68Ga-PSMA uptake in salivary glands","volume":"8","author":"van Kalmthout","year":"2018","journal-title":"EJNMMI Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"19938","DOI":"10.1038\/s41598-024-70417-3","article-title":"3D small-scale dosimetry and tumor control of 225Ac radiopharmaceuticals for prostate cancer","volume":"14","author":"Peter","year":"2024","journal-title":"Sci Rep"},{"key":"B52","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.clon.2020.11.028","article-title":"Systemic radiotherapy of bone metastases with radionuclides","volume":"33","author":"Murray","year":"2021","journal-title":"Clin Oncol R Coll Radiol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/pharmaceutics15010252","article-title":"Targeted radiation and immune therapies-advances and opportunities for the treatment of prostate cancer","volume":"15","author":"Muralidhar","year":"2023","journal-title":"Pharmaceutics"},{"key":"B54","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/01.rlu.0000109721.58471.44","article-title":"Results of strontium-89 therapy in patients with prostate cancer resistant to chemotherapy","volume":"29","author":"Gunawardana","year":"2004","journal-title":"Clin Nucl Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.3390\/cancers15123133","article-title":"Innovation in radionuclide therapy for the treatment of prostate cancers: radiochemical perspective and recent therapeutic practices","volume":"15","author":"Deshayes","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1007\/s00259-025-07627-y","article-title":"Therapeutic outcomes of 225Ac\/177Lu-PSMA combination therapy in advanced metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"53","author":"Belabaci","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B58","doi-asserted-by":"publisher","first-page":"879","DOI":"10.21873\/anticanres.16881","article-title":"Current status of prostate-specific membrane antigen-targeted alpha radioligand therapy in prostate cancer","volume":"44","author":"Yamamichi","year":"2024","journal-title":"Anticancer Res"}],"container-title":["Oncology Reviews"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/or.2026.1834484\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:05:25Z","timestamp":1784095525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/or.2026.1834484\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":58,"alternative-id":["10.3389\/or.2026.1834484"],"URL":"https:\/\/doi.org\/10.3389\/or.2026.1834484","relation":{},"ISSN":["1970-5557"],"issn-type":[{"value":"1970-5557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1834484"}}